Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$102.56 -1.5%	$86.93	$60.40 ▼ $106.83	$19.76B	0.9	2.30 million shs	1.43 million shs
RYTM Rhythm Pharmaceuticals	$89.20 -1.6%	$67.14	$40.61 ▼ $94.80	$5.77B	2.26	590,318 shs	624,068 shs
SMMT Summit Therapeutics	$26.20 -5.2%	$22.82	$8.71 ▼ $36.91	$20.52B	-1.01	3.76 million shs	3.00 million shs
TEVA Teva Pharmaceutical Industries	$16.08 -1.4%	$17.01	$12.47 ▼ $22.80	$18.71B	0.6	10.32 million shs	12.14 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	-1.55%	+4.46%	+3.12%	+41.41%	+35.77%
RYTM Rhythm Pharmaceuticals	-1.63%	+2.88%	+45.09%	+44.48%	+71.27%
SMMT Summit Therapeutics	-5.18%	+4.80%	+29.96%	+6.46%	+181.42%
TEVA Teva Pharmaceutical Industries	-1.44%	-1.89%	-5.81%	+18.19%	-1.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INSM Insmed	3.96 of 5 stars	2.5	4.0	0.0	4.3	2.8	1.7	0.6
RYTM Rhythm Pharmaceuticals	3.1846 of 5 stars	2.5	1.0	0.0	4.3	2.6	0.8	0.6
SMMT Summit Therapeutics	3.0858 of 5 stars	4.4	3.0	0.0	0.0	2.1	1.7	0.0
TEVA Teva Pharmaceutical Industries	4.1458 of 5 stars	4.6	4.0	0.8	0.0	2.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSM Insmed	3.00	Buy	$108.47	5.76% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.93	3.06% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	32.32% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	53.70% Upside

Current Analyst Ratings Breakdown

Latest RYTM, INSM, SMMT, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSM Insmed	$363.71M	53.49	N/A	N/A	$1.60 per share	64.10
RYTM Rhythm Pharmaceuticals	$136.86M	41.46	N/A	N/A	$0.35 per share	254.86
SMMT Summit Therapeutics	$700K	27,797.08	N/A	N/A	$0.53 per share	49.43
TEVA Teva Pharmaceutical Industries	$16.62B	1.11	$3.32 per share	4.85	$4.74 per share	3.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.11	0.96	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest RYTM, INSM, SMMT, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	N/A	N/A	N/A	$4.34 billion	N/A
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSM Insmed	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.29%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSM Insmed	11.38	5.86	5.44
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
SMMT Summit Therapeutics	N/A	10.63	10.63
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSM Insmed	N/A
RYTM Rhythm Pharmaceuticals	N/A
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
INSM Insmed	3.00%
RYTM Rhythm Pharmaceuticals	6.10%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

RYTM, INSM, SMMT, and TEVA Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Boosted by Victory Capital Management Inc.

1 hour ago | marketbeat.com

Migdal Insurance & Financial Holdings Ltd. Buys 300,000 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 18 at 9:59 AM | marketbeat.com

Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters

July 18 at 3:06 AM | fool.com

Envestnet Asset Management Inc. Cuts Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 15, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Penserra Capital Management LLC

July 13, 2025 | marketbeat.com

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

July 11, 2025 | zacks.com

Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders

July 10, 2025 | msn.com

Teva (TEVA) Receives a Buy from Leader Capital Markets

July 10, 2025 | theglobeandmail.com

Stock Traders Buy High Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

July 9, 2025 | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Boosted by IFM Investors Pty Ltd

July 8, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

July 7, 2025 | marketbeat.com

Leader Capital Markets Keeps Their Buy Rating on Teva (TEVA)

July 7, 2025 | theglobeandmail.com

Teva Pharmaceutical Industries Ltd. ADR Stock Grades - Barron's

July 7, 2025 | barrons.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Buy" from Analysts

July 7, 2025 | marketbeat.com

Teacher Retirement System of Texas Reduces Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 6, 2025 | marketbeat.com

Cambridge Investment Research Advisors Inc. Purchases 41,600 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 5, 2025 | marketbeat.com

Harel Insurance Investments & Financial Services Ltd. Buys 22,044,407 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 4, 2025 | marketbeat.com

Straight Path Wealth Management Decreases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 3, 2025 | marketbeat.com

WCM Investment Management LLC Increases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by DAVENPORT & Co LLC

July 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

July 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Russell Rebalance: 3 Stocks Ready to Move Higher
By Chris Markoch | June 20, 2025
View Russell Rebalance: 3 Stocks Ready to Move Higher

RYTM, INSM, SMMT, and TEVA Company Descriptions

Insmed NASDAQ:INSM

$102.56 -1.61 (-1.55%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$102.74 +0.17 (+0.17%)

As of 07/18/2025 06:15 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Rhythm Pharmaceuticals NASDAQ:RYTM

$89.20 -1.48 (-1.63%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$90.39 +1.19 (+1.33%)

As of 07/18/2025 07:55 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$26.20 -1.43 (-5.18%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.36 +0.16 (+0.60%)

As of 07/18/2025 07:58 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.08 -0.23 (-1.41%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$16.10 +0.02 (+0.12%)

As of 07/18/2025 07:56 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time